Can FDG-PET assess the response to chemotherapy and predict tissue necrosis in osteosarcoma and Ewing sarcoma?

Folia Med (Plovdiv). 2024 Apr 30;66(2):196-202. doi: 10.3897/folmed.66.e117148.

Abstract

Osteosarcoma (OS) and Ewing sarcoma (ES) represent the pediatric population's most common malignant bone tumors. 18-Fluorodeoxyglucose positron emission tomography has been shown to be effective in both the diagnostic and staging phases of cancer treatment. In recent years, some studies have also explored the possibility that FDG-PET could have a prognostic role.

Keywords: Ewing sarcoma necrosis osteosarcoma PET prognosis.

Publication types

  • Review

MeSH terms

  • Bone Neoplasms* / diagnostic imaging
  • Bone Neoplasms* / drug therapy
  • Bone Neoplasms* / pathology
  • Fluorodeoxyglucose F18*
  • Humans
  • Necrosis
  • Osteosarcoma* / diagnostic imaging
  • Osteosarcoma* / drug therapy
  • Osteosarcoma* / pathology
  • Positron-Emission Tomography*
  • Prognosis
  • Radiopharmaceuticals*
  • Sarcoma, Ewing* / diagnostic imaging
  • Sarcoma, Ewing* / drug therapy
  • Sarcoma, Ewing* / pathology

Substances

  • Fluorodeoxyglucose F18
  • Radiopharmaceuticals